Elite Pharmaceuticals, Inc. Finance Lease, Principal Payments
Elite Pharmaceuticals, Inc. (ELTP) reported Finance Lease, Principal Payments of $96.07 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:FinanceLeasePrincipalPayments · last filed 2026-08-13
- Elite Pharmaceuticals, Inc. finance lease, principal payments for the quarter ending 2026-06-30 was $96.07K, a 4.23% increase year-over-year.
- Elite Pharmaceuticals, Inc. finance lease, principal payments for the quarter ending 2026-03-31 was $97.19K, a 7.93% increase year-over-year.
- Elite Pharmaceuticals, Inc. finance lease, principal payments for the quarter ending 2025-12-31 was $96.59K, a 9.81% increase year-over-year.
- Elite Pharmaceuticals, Inc. finance lease, principal payments for the quarter ending 2025-09-30 was $94.36K, a 8.65% increase year-over-year.
- Elite Pharmaceuticals, Inc. finance lease, principal payments for fiscal 2026 was $380.32K, a 13.13% increase from fiscal 2025.
- Elite Pharmaceuticals, Inc. finance lease, principal payments for fiscal 2025 was $336.19K, a 3.99% decline from fiscal 2024.
- Elite Pharmaceuticals, Inc. finance lease, principal payments for fiscal 2024 was $350.17K.
| Period end | Finance Lease, Principal Payments 3 month | Finance Lease, Principal Payments 6 month | Finance Lease, Principal Payments 9 month | Finance Lease, Principal Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $96.07K 10-Q · filed 2026-08-13 | $193.26K derived: sum of 2 quarters · filed 2026-08-13 | $289.85K derived: sum of 3 quarters · filed 2026-08-13 | $384.21K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $97.19K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29 | $193.78K derived: sum of 2 quarters · filed 2026-06-29 | $288.14K derived: sum of 3 quarters · filed 2026-06-29 | $380.32K 10-K · filed 2026-06-29 |
| 2025-12-31 | $96.59K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-17 | $190.95K derived: sum of 2 quarters · filed 2026-02-17 | $283.13K 10-Q · filed 2026-02-17 | $373.18K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-09-30 | $94.36K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-14 | $186.54K 10-Q · filed 2025-11-14 | $276.58K derived: sum of 3 quarters · filed 2026-08-13 | $364.55K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $92.18K 10-Q · filed 2026-08-13 | $182.22K derived: sum of 2 quarters · filed 2026-08-13 | $270.19K derived: sum of 3 quarters · filed 2026-08-13 | $357.04K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $90.05K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29 | $178.01K derived: sum of 2 quarters · filed 2026-06-29 | $264.86K derived: sum of 3 quarters · filed 2026-06-29 | $336.19K 10-K · filed 2026-06-29 |
| 2024-12-31 | $87.96K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-17 | $174.81K derived: sum of 2 quarters · filed 2026-02-17 | $246.14K 10-Q · filed 2026-02-17 | |
| 2024-09-30 | $86.85K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-14 | $158.18K 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | $71.33K 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | $350.17K 10-K · filed 2025-06-30 |